Analyst Price Target is $30.50
▲ +63.98% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Meridian Bioscience in the last 3 months. The average price target is $30.50, with a high forecast of $34.00 and a low forecast of $27.00. The average price target represents a 63.98% upside from the last price of $18.60.
Current Consensus is
The current consensus among 2 contributing investment analysts is to buy stock in Meridian Bioscience. This rating has held steady since October 2020, when it changed from a Hold consensus rating.
Meridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products; and sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.